The structure of the thyroid stimulating hormone receptor (TSHR) has attracted an unusual amount of discussion. Different authors have described a wide variety of receptor forms, with molecular masses varying from 90 to 500 kDa, and comprising one to three subunits (reviewed in 1).
receptors is different. The LH (7) and FSH (8) receptors are expressed in target cells as glycosylated monomers. Unexpectedly, western blots of receptor immunopurified from thyroid extracts, performed with different monoclonal antibodies raised against the extracellular or the intracellular parts of the receptor, showed that the TSHR is in fact a heterodimer (9) . It comprises an a extracellular subunit (ϳ53 kDa) and a broad b transmembrane and intracellular subunit (30-42 kDa), held together by disulphide bridges. These subunits were named a and b by analogy with the insulin receptor, which is also post-translationally cleaved.
The maturation of the TSHR by post-translational cleavage is unique among G-protein-coupled receptors; it has to be differentiated from ligand-mediated enzymatic cleavage of the thrombin receptor during the process of receptor activation (10) .
In thyroid tissue, the cleavage is almost complete. Only traces of precursors can be detected. This is reminiscent of the model suggested by Rees Smith et al. (11) , but different from many others proposed at the same period on the basis of studies using similar methodological approaches.
Contrasting with the situation found in the thyroid, a much more complex pattern is observed in transfected cells in which mixed mature and immature forms of the receptor accumulate (12) . This is probably due to the overexpression of the receptor in these cells and to the saturation of the cellular machinery necessary for the processing of the receptor. Monomeric precursors of 95 kDa and 120 kDa accumulate in these cells. Two steps are involved in the glycosylation of proteins: first, the addition of high mannose residues in the endoplasmic reticulum, and secondly the trimming of the residues and addition of complex oligosaccharides in the Golgi apparatus. Endoglycosidase H, specific for precursor high-mannose moieties of glycoproteins, can be used to identify precursor species. Indeed, the 95 kDa monomer that accumulates mainly in transfected cells is sensitive to that enzyme and corresponds to a highmannose precursor of the TSHR. It is also the first species to be observed on pulse-chase studies and undergoes subsequent mature glycosylation and cleavage (12) .
A second 120 kDa monomer is observed on western blots in transfected cells. It corresponds to the fully glycosylated, but uncleaved, monomer.
Apart from monomeric precursors, a-and b-subunits are also detected in transfected cells, showing that the enzyme involved in TSHR cleavage is not cell-specific. The a-subunit is, however, more glycosylated than in the thyroid (with an apparent molecular mass of 60 kDa), without any deleterious effect on receptor function. Two different b-subunits are observed instead of a broad b band in the thyroid. This raised the possibility of the existence of different cleavage sites (12) .
The 95 kDa monomer that accumulates in high concentration in transfected cells may, in many cases, have been mistaken for the mature receptor. Endoglycosidase treatment is necessary to determine its nature. Many investigators have tried to overproduce the TSHR or its extracellular domain in different eucaryotic cells, including the baculovirus systems. Because of the complex maturation of the TSHR, this overproduction yielded an increased production of an unprocessed and non-functional receptor (12) (13) (14) .
Shedding of TSHR ectodomain
The quantification of a-and b-subunit concentrations in thyroid membranes using monoclonal antibodies yielded an unexpected difference: a 2.5-to 3-fold excess of bover a-subunits. This apparent lack of a-subunits led to the hypothesis that the a-subunit might be shed from cell membranes and released into the extracellular space or the bloodstream (9) .
This shedding mechanism has been observed for several surface proteins or receptors (15, 16) . For some receptors, the shedding is sometimes increased by ligand binding or by protein kinase C activation and in this way may be involved in the down-regulation of receptor function. In the case of the TSHR, another reason for studying shedding was that it might also be implicated in the development of autoimmune diseases.
The use of a double-determinant (sandwich type) immunoassay using two additive monoclonal antibodies allowed detection of a spontaneous shedding of the a-subunit of the receptor from primary cultures of human thyrocytes and transfected cells (17) . Western blot analysis revealed that the shed receptor corresponded to the entire a-subunit. This soluble receptor was able to bind TSH specifically, with an affinity similar to that of the full-length receptor.
In addition, TSH elicited a limited but significant increase in receptor shedding (25-30%) in this cellular system. In vivo, there was a 2.5-to 3-fold excess of b-subunits in the thyroid membranes, suggesting that a greater proportion of the a-subunits were shed.
Another problem was the identification of the class of proteases involved in the maturation of the TSHR. A great number of membrane proteins are processed by serine proteases related to subtilisin (18) . This is the case for the insulin receptor, which is processed by furin in the late Golgi compartment. However, we initially detected differences in the cleavage of TSH and insulin receptors. In particular, the cleavage of the TSHR, unlike that of the insulin receptor, does not occur when mature glycosylation is impeded. This suggested different compartmentalization of the respective convertases (12) . Furthermore, the use of inhibitors of different steps of receptor intracellular trafficking showed that TSHR cleavage occurs at, or very near, the cell surface (17) .
To identify the nature of the TSHR convertase, a large number of protease inhibitors belonging to different classes were used. All of them were inefficient or had a very limited effect, suggesting that an unusual convertase was involved. At the same time the cleavage and shedding of another membrane protein -the proinflammatory cytokine, tumour necrosis factor a (TNFa) -was found to be completely inhibited by a novel compound, a hydroxamic acid, BB2116 (19) . This compound also inhibited the activity of a variety of matrix metalloproteases (MMP). BB2116 was found to inhibit markedly the cleavage and subsequent shedding of the TSHR. Thus TSHR convertase seemed to share some similarities with MMP (17) . These proteases are secreted from the cells and their primary role is to degrade extracellular matrix proteins. However, unexpected properties for an enzyme of this class were later found, in particular its insensitivity to tissue inhibitors of matrix metalloproteases (S de Bernard, unpublished observations). This strongly suggests that TSHR convertase, although related to MMP (Fig. 1) could belong to a different class of enzymes.
The shedding of the TSHR is a two-step process: the first step corresponds to the cleavage of the proreceptor and the second step corresponds to the reduction of disulphide bonds.
As stated before, the cleavage of the TSHR shares some similarities with that of other membrane proteins such as TNFa, and a related mechanism may be involved. However, the eventual involvement of the reduction of disulphide bonds in the shedding of other membrane proteins has not been studied previously.
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Figure 1 Schematic representation of the two steps involved in the shedding of the TSH receptor (TSHR). The first step corresponds to the cleavage of the ϳ120 kDa precursor by a matrix metalloprotease-like enzyme (MMP-like), leading to the formation of a heterodimeric receptor (17) . The second step corresponds to the reduction of the disulphide bonds holding the two subunits of the receptor by protein disulphide isomerase (PDI) (20) .
The use of a membrane-impermeant sulphydryl reagent, 5,5 0 -dithiobis(2-nitrobenzoic acid) (DTNB), enabled us to observe that reduction of disulphide bonds of the TSHR also takes place at the cell surface and may correspond to a catalysed step (20) . In fact, only three enzymes have been shown to catalyse disulphide oxidoreduction reactions in mammalian cells: protein disulphide isomerase (PDI), thioredoxin and glutaredoxin. Only PDI and thioredoxin have been detected at the cell surface of mammalian cells.
The use of two inhibitors, including specific monoclonal antibodies against PDI, demonstrated that cellsurface-associated PDI is involved in the second step of receptor shedding (20) . This is an unusual function for PDI. PDI is localized essentially in the endoplasmic reticulum, where it catalyses the disulphide bridge formation, isomerization and reduction necessary for the correct folding of newly synthesized proteins (21) . The involvement of PDI in the shedding process may be extended to other membrane proteins, and remains to be explored.
A soluble form of TSHR that may originate from shedding has also been detected in human serum (17) . TSHR-related peptide-like immunoreactivity (22) and TSH binding protein (23) have previously been detected in human serum. It has been proposed, by analogy with the LH/CG receptor (2) , that alternative spliced forms of the TSHR are expressed that may also yield soluble forms of receptor (24, 25) . However, these truncated mRNAs were detected by PCR and may represent a low concentration of the mRNAs. Furthermore, we do not know whether the truncated mRNAs that were detected are efficiently translated into proteins.
Conclusions
Considerable progress in elucidating the structure and funtion of the TSHR has been made, but several important problems remain to be solved.
The exact cleavage sites of the TSHR are not known. Immunopurification of receptor subunits, followed by protein sequencing, should allow us to establish the precise site(s). They are expected to be located in a specific region of the TSHR ectodomain that displays no homology with the gonadotropin receptors. Mutagenesis experiments will lead to an understanding of the part played by cleavage in TSHR function. The fate and function of the free b-subunits that are present in excess in thyroid membranes are also unknown.
Finally, more experiments are required to discover whether there is a correlation between the serum sTSHR and specific pathological conditions such as autoimmune diseases or thyroid cancers.
